PHARMACY

Hy-Vee buys Econofoods pharmacy

BY Drew Buono

GALESBURG, Ill. Hy-Vee has bought the Econofoods pharmacy in Galesburg, according to published reports. This, along with the closing of another Econofoods store in the area, will completely eliminate Nash Finch in Illinois.

Hy-Vee operated three pharmacies in Galesburg; one at each of its two supermarkets as well as a satellite pharmacy at the Galesburg Clinic.

The two Econofoods stores, including the one bought by Hy-Vee will be closed on Aug. 22.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Gestational diabetes results in increased risk for Type 2 diabetes

BY Drew Buono

NEW YORK Gestational diabetes greatly increases a woman’s risk of developing Type 2 diabetes later on in life, a new study confirms, according to Reuters.

Gestational diabetes is a known risk factor for Type 2 diabetes. Denice Feig of the University of Toronto and her team looked at 633,449 women who gave birth in Toronto between 1995 and 2002. A total of 21,823 (3.3 percent) of the women were diagnosed with gestational diabetes.

While just 2 percent of the women who didn’t have gestational diabetes went on to develop Type 2 diabetes during the 9-year follow-up period, 19 percent of those with gestational diabetes did, the researchers found.

Moreover, they say the strongest risk factor for Type 2 diabetes was gestational diabetes, which increased risk more than 37-fold.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Russian antihistamine appears effective against Alzheimer’s

BY Alaric DeArment

NEW YORK A study that lasted a year and a half has found that an antihistamine developed in the former Soviet Union may be able to stabilize Alzheimer’s disease.

The study, presented at the International Conference on Alzheimer’s Disease, found that the drug Dimebon could stabilize the disease for at least the time of the study. Researchers tested the drug against a placebo in 183 patients in Russia who had mild to moderate Alzheimer’s.

Conditions of patients who received the placebo deteriorated, while those of the people who received Dimebon improved or deteriorated only slightly.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES